| 顾林昊,李丽莉,戴珒.新冠体外诊断试剂国内外监管差异及其根源分析[J].中国药事,2023,(2):142-149 |
| 新冠体外诊断试剂国内外监管差异及其根源分析 |
| Comparative Analysis on Differences and Causes of Regulating COVID-19 In Vitro Diagnostic Reagents |
| |
| DOI：10.16153/j.1002-7777.2023.02.003 |
| 中文关键词: 新型冠状病毒肺炎 体外诊断试剂 差异来源分析 防疫政策 审批流程 审评要求 |
| 英文关键词: COVID-19 IVD cause analysis of diff erences COVID-19 prevention policies evaluation process evaluation requirements |
| 基金项目:北京市科技计划——创新品种及平台培育项目——新冠肺炎诊断试剂科技攻关技术平台(编号 Z201100005420022) |
|
| 摘要点击次数: 856 |
| 全文下载次数: 382 |
| 中文摘要: |
| 目的：探讨新冠体外诊断试剂监管与公共卫生政策的关系，从监管科学角度总结我国防控新冠疫情的经验，为应急监管体系的持续改进提供参考。方法：比对中、美、欧盟、WHO这几个主要国家或组织的审评流程、审评要求、产品数据等，并分析差异原因。结果与结论：各国(组织)在新冠疫情中对于新冠体外诊断试剂的监管与其自身国情相关，尤其是产品应用场景方面的差异。我国对体外诊断试剂的监管与公共卫生政策密切关联，在对抗新冠疫情中起到了积极作用。 |
| 英文摘要: |
| Objective: To explore the relationship between the regulations of COVID-19 in-vitro diagnostic (IVD) reagents and public health practices, summarize the experience of fi ghting the COVID-19 from a regulatory science perspective and provide reference for continually improving the emergency regulation system. Methods: The approval procedures, requirements and product data of different countries/organizations and the reasons for differences were analyzed. Results and Conclusion: The supervisions of these IVD products in different countries/organizations are consistent with the diff erent conditions especially the context diff erences of product application. The supervision of IVD reagents in China is closely related to public health policies and has played a positive role in fi ghting against COVID-19. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |